Geriatric assessment for oncologists

The world is experiencing aging of its population. Age-specific incidence rates of cancer are higher and cancer is now recognized as a part of aging. Treating older patients can be challenging. The clinical behavior of some tumors changes with age and the aging process itself brings physiological ch...

Full description

Bibliographic Details
Main Authors: Beatriz Korc-Grodzicki, Holly M. Holmes, Armin Shahrokni
Format: Article
Language:English
Published: China Anti-Cancer Association 2015-12-01
Series:Cancer Biology & Medicine
Subjects:
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/880
id doaj-47a0679cd8be4d5c93d164579bbf4fa1
record_format Article
spelling doaj-47a0679cd8be4d5c93d164579bbf4fa12020-11-25T01:13:25ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412015-12-0112426127410.7497/j.issn.2095-3941.2015.00822015000082Geriatric assessment for oncologistsBeatriz Korc-Grodzicki0Holly M. Holmes1Armin Shahrokni2Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA;Division of Geriatric and Palliative Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USAMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA;The world is experiencing aging of its population. Age-specific incidence rates of cancer are higher and cancer is now recognized as a part of aging. Treating older patients can be challenging. The clinical behavior of some tumors changes with age and the aging process itself brings physiological changes leading to decline in the function of organs. It is essential to identify those patients with longer life expectancy, potentially more likely to benefit from aggressive treatment <i>vs</i>. those that are more vulnerable to adverse outcomes. A primary determination when considering therapy for an older cancer patient is a patient's physiologic, rather than chronologic age. In order to differentiate amongst patients of the same age, it is useful to determine if a patient is fit or frail. Frail older adults have multiple chronic conditions and difficulties maintaining independence. They may be more vulnerable to therapy toxicities, and may not have substantial lasting benefits from therapy. Geriatric assessment (GA) may be used as a tool to determine reversible deficits and devise treatment strategies to mitigate such deficits. GA is also used in treatment decision making by clinicians, helping to risk stratify patients prior to potentially high-risk therapy. An important practical aspect of GA is the feasibility of incorporating it into a busy oncology practice. Key considerations in performing the GA include:available resources, patient population, GA tools to use, and who will be responsible for using the GA results and develop care plans. Challenges in implementing GA in clinical practice will be discussed.http://www.cancerbiomed.org/index.php/cocr/article/view/880Geriatric oncologygeriatric assessment (GA)frailty
collection DOAJ
language English
format Article
sources DOAJ
author Beatriz Korc-Grodzicki
Holly M. Holmes
Armin Shahrokni
spellingShingle Beatriz Korc-Grodzicki
Holly M. Holmes
Armin Shahrokni
Geriatric assessment for oncologists
Cancer Biology & Medicine
Geriatric oncology
geriatric assessment (GA)
frailty
author_facet Beatriz Korc-Grodzicki
Holly M. Holmes
Armin Shahrokni
author_sort Beatriz Korc-Grodzicki
title Geriatric assessment for oncologists
title_short Geriatric assessment for oncologists
title_full Geriatric assessment for oncologists
title_fullStr Geriatric assessment for oncologists
title_full_unstemmed Geriatric assessment for oncologists
title_sort geriatric assessment for oncologists
publisher China Anti-Cancer Association
series Cancer Biology & Medicine
issn 2095-3941
2095-3941
publishDate 2015-12-01
description The world is experiencing aging of its population. Age-specific incidence rates of cancer are higher and cancer is now recognized as a part of aging. Treating older patients can be challenging. The clinical behavior of some tumors changes with age and the aging process itself brings physiological changes leading to decline in the function of organs. It is essential to identify those patients with longer life expectancy, potentially more likely to benefit from aggressive treatment <i>vs</i>. those that are more vulnerable to adverse outcomes. A primary determination when considering therapy for an older cancer patient is a patient's physiologic, rather than chronologic age. In order to differentiate amongst patients of the same age, it is useful to determine if a patient is fit or frail. Frail older adults have multiple chronic conditions and difficulties maintaining independence. They may be more vulnerable to therapy toxicities, and may not have substantial lasting benefits from therapy. Geriatric assessment (GA) may be used as a tool to determine reversible deficits and devise treatment strategies to mitigate such deficits. GA is also used in treatment decision making by clinicians, helping to risk stratify patients prior to potentially high-risk therapy. An important practical aspect of GA is the feasibility of incorporating it into a busy oncology practice. Key considerations in performing the GA include:available resources, patient population, GA tools to use, and who will be responsible for using the GA results and develop care plans. Challenges in implementing GA in clinical practice will be discussed.
topic Geriatric oncology
geriatric assessment (GA)
frailty
url http://www.cancerbiomed.org/index.php/cocr/article/view/880
work_keys_str_mv AT beatrizkorcgrodzicki geriatricassessmentforoncologists
AT hollymholmes geriatricassessmentforoncologists
AT arminshahrokni geriatricassessmentforoncologists
_version_ 1725162450341330944